Role of splenectomy in hepatic resection for hepatocellular carcinoma associated with severe cirrhosis and hypersplenism

Hepatology Research

Volumn 14, Issue 1, 1999, Pages 35-48

  Nagasue, Naofumi ^a   Kohno, Hitoshi ^a   Yamanoi, Akira ^a   Ohmori, Haruki ^a   Kumar Dhar, Dipok ^a   Makino, Yoshinari ^a   Kimoto, Takeo ^a   Tachibana, Mitsuo ^a  

^a SHIMANE UNIVERSITY   (Japan)

Author keywords

Endothelin 1; Hepatic resection; Hepatocellular carcinoma; Hypersplenism; Liver cirrhosis; Portal hypertension; Splenectomy

Indexed keywords

ENDOTHELIN 1;

ADULT; AGED; ARTICLE; CHRONIC LIVER DISEASE; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HISTOPATHOLOGY; HUMAN; HYPERSPLENISM; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER RESECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PORTAL HYPERTENSION; PORTAL VEIN BLOOD FLOW; PORTAL VEIN BLOOD PRESSURE; PRIORITY JOURNAL; SPLEEN BLOOD FLOW; SPLENECTOMY; SURVIVAL RATE;

EID: 0033010452     PISSN: 09284346     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1386-6346(98)00104-1     Document Type: Article

References (40)

1. Okuda K., Fujimoto I., Hanai A., Urano Y. Changing incidence of hepatocellular carcinoma in Japan. Cancer Res. 47:1987;4967-4972.
2. Kacrynski J., Hansson G., Norkrans G., Wallerstedt S. Lack of correlation between hepatitis B virus infection and the increasing incidence of primary liver cancer in Sweden. Acta Oncol. 30:1991;311-313.
3. Colombo M., De Franchis R., Del Ninno E., Sangiovanni A., De Fazio C., Tommasini M. et al. Hepatocellular carcinoma in Italian patients with cirrhosis. N. Engl. J. Med. 325:1991;675-680.
4. Tsukama H., Hiyama T., Tanaka S., Nakao M., Yabauchi T., Kitamura T. et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N. Engl. J. Med. 328:1993;1797-1801.
5. Benvegnu L., Alberti A. Risk factors and prevention of hepatocellular carcinoma in HCV infection. Dig. Dis. Sci. 41:1996;49-55.
6. Iwatsuki S., Gordon R.D., Shaw B.W. Jr., Starzl T.E. Role of liver transplantation in cancer therapy. Ann. Surg. 202:1985;401-407.
7. Mazzaferro V., Regalia E., Doci R., Andreola S., Pulvirenti A., Bozzetti F. et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N. Engl. J. Med. 334:1996;693-699.
8. Banti G. Splenomegalie mit Leberzirrhose. Beitr. Pathol. Anat. 24:1898;21-33.
9. Sato T., Takahashi M., Suda Y., Watanabe T. Effect of splenectomy on histopathology and functions of the liver in Banti's syndrome. Tohoku J. Exp. Med. 81:1963;17-45.
10. Deaver J.B. Splenic enlargement with cirrhosis of the liver. Ann. Surg. 88:1928;355-360.
11. Mayo W.J. A review of 500 splenectomies with special reference to mortality and end results. Ann. Surg. 88:1928;409-415.
12. Larrabee R.C. Chronic congestive splenomegaly and its relationship to Banti's disease. Am. J. Med. Sci. 188:1934;745-760.
13. Rousselot L.M. The role of congestion (portal hypertension) in so-called Banti's syndrome: a clinical and pathologic study of thirty-one cases with the late results following splenectomy. J. Am. Med. Assoc. 107:1936;1788-1793.
14. Higgins G.M., Priestley J.T. Experimental pathlogy of the liver-VI. Restoration of the liver in white rats after partial removal and splenectomy. Arch. Pathol. 13:1932;573-583.
15. Ohira M., Umeyama K., Taniura M., Yamashita T., Morisawa S. An experimental study of a splenic inhibitory factor influencing hepatic regeneration. Surg. Gynecol. Obstet. 164:1987;438-444.
16. Shiratori Y., Tanaka M., Hai K., Kawase T., Shiina S., Sugimoto T. Role of endotoxin-responsive macrophages in hepatic injury. Hepatology. 11:1990;183-192.
17. Suzuki S., Nakamura S., Serizawa A., Sakaguchi T., Konno H., Muro H. et al. Role of Kupffer cells and the spleen in modulation of endotoxin-induced liver injury after partial hepatectomy. Hepatology. 24:1996;219-225.
18. Okuaki Y., Miyazaki H., Zeniya M., Ishikawa T., Ohkawa Y., Tsuno S. et al. Splenectomy-reduced hepatic injury induced by ischemia/reperfusion in the rat. Liver. 16:1996;188-194.
19. Hashimoto H., Taruya E., Yamashita T., Ishikawa T., Taniura M., Umeyama K. The effect of splenectomy in the experimental liver injury induced by carbon tetrachloride. Acta Hepatol. Jpn. 25:1984;907-914.
20. Miyazaki H., Sata H., Kawabe T., Okuyama S., Takahashi H., Negishi M. et al. Role of the spleen on liver fibrogenesis in experimental liver fibrosis. Acta Hepatol. Jpn. 29:1988;703-704.
21. Maddison F.E. Embolic therapy of hypersplenism. Invest. Radiol. 8:1973;280-281.
22. Witte C.L., Witte M.H., Renert W., O'Mara R.E., Lilien D.L. Splenic artery ligation in selected patients with hepatic cirrhosis and in Sprague-Dawley rats. Surg. Gynecol. Obstet. 142:1976;1-12.
23. Hirai K., Kawazoe Y., Yamashita K., Arima N., Hino K., Eguchi S. et al. A case of liver cirrhosis with hypersplenism undertaken transcatheter splenic arterial embolization (TSAE). Acta Hepatol. Jpn. 26:1985;1681-1685.
24. Tashiro K., Akagi K., Azuma K., Ikeda K., Nomiyama K., Sakino I. et al. Efficacy of partial splenic embolization for the treatment of liver cirrhosis with hypersplenism: a case report. Acta Hepatol. Jpn. 37:1996;513-519.
25. Porter B.A., Frey C.F., Link D.P., Lantz B.M., Pimstone N.R. Splenic embolization monitored by the video dilution technique. Am. J. Roentgenol. 141:1983;1063-1065.
26. Perez-Tamayo R., Romero R. Role of the spleen in regeneration of the liver: an experimental study. Lab. Invest. 7:1958;248-257.
27. Sakai A., Taha M., Kashiwabara H., Pfeffermann R., Kountz S.L. On the origin of the regeneration factor. Surg. Gynecol. Obstet. 145:1977;889-894.
28. Miyata S., Kihara H. Selective inhibition of DNA synthesis by a protein released from spleen cells. J. Cell. Physiol. 110:1982;315-317.
29. Housset C.N., Rockey D.C., Friedman S.L., Bissell D.M. Hepatic lipocytes: a major target for endothelin-1. J. Hepatol. (Suppl. 2). 22:1995;55-60.
30. Mallat A., Lotersztajn S. Multiple hepatic functions of endothelin-1: physiopathological relevance. J. Hepatol. 25:1996;405-413.
31. Rockey D. The cellular pathogenesis of portal hypertension: stellate cell contractility, endothelin, and nitric oxide. Hepatology. 25:1997;2-5.
32. Uchihara M., Izumi N., Sato C., Marumo F. Clinical significance of elevated plasma endothelin concentration in patients with cirrhosis. Hepatology. 16:1992;95-99.
33. Asbert M., Gines A., Gines P., Jimenez W., Claria J., Salo J. et al. Circulating levels of endothelin in cirrhosis. Gastroenterology. 104:1993;1485-1491.
34. Moller S., Emmeluth C., Henriksen J.H. Elevated circulating plasma endothelin-1 concentrations in cirrhosis. J. Hepatol. 19:1993;285-290.
35. Gerbes A.L., Moller S., Gulberg V., Henriksen J.H. Endothelin-1 and -3 plasma concentrations in patients with cirrhosis: role of splanchnic and renal passage and liver function. Hepatology. 21:1995;735-739.
36. Bernardi M., Gulberg V., Colantoni A., Trevisani F., Gasbarrini A., Gerbes A.L. Plasma endothelin-1 and -3 in cirrhosis: relationship with systemic hemodynamics, renal function and neurohumoral systems. J. Hepatol. 24:1996;161-168.
37. Pinzani M., Milani S., De Franco R., Grappone C., Caligiuri A., Gentilini A. et al. Endothelin-1 is overexpressed in human cirrhotic liver and exerts multiple effects on activated hepatic stellate cells. Gastroenterology. 110:1996;534-548.
38. Holdsworth R.J., Irving A.D., Cuschieri A. Postsplenectomy sepsis and its mortality rate: actual versus perceived risks. Br. J. Surg. 78:1991;1031-1038.
39. Jessup J.M., Pellis N.R., Kahan B.D. The spleen as a source of nonspecific suppressor cells in the tumor-bearing mouse. J. Surg. Res. 28:1980;460-465.
40. Meyer J.D., Argyris B.F., Meyer J.A. Splenectomy, suppressor cell activity, survival in tumor bearing rats. J. Surg. Res. 29:1980;527-532.